Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Gains from Investment Securities: 2016-2025

Historic Gains from Investment Securities for Akebia Therapeutics (AKBA) over the last 8 years, with Sep 2025 value amounting to -$1.5 million.

  • Akebia Therapeutics' Gains from Investment Securities fell 271.03% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 183.52%. This contributed to the annual value of -$622,000 for FY2024, which is 145.70% down from last year.
  • Per Akebia Therapeutics' latest filing, its Gains from Investment Securities stood at -$1.5 million for Q3 2025, which was down 120.97% from $7.0 million recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Gains from Investment Securities peaked at $51.3 million during Q4 2022, and registered a low of -$11.0 million during Q3 2022.
  • In the last 3 years, Akebia Therapeutics' Gains from Investment Securities had a median value of $613,000 in 2024 and averaged $171,889.
  • As far as peak fluctuations go, Akebia Therapeutics' Gains from Investment Securities plummeted by 25,245.45% in 2021, and later surged by 5,519.98% in 2022.
  • Akebia Therapeutics' Gains from Investment Securities (Quarterly) stood at -$946,000 in 2021, then spiked by 5,519.98% to $51.3 million in 2022, then crashed by 113.29% to -$6.8 million in 2023, then soared by 110.61% to $723,000 in 2024, then slumped by 271.03% to -$1.5 million in 2025.
  • Its last three reported values are -$1.5 million in Q3 2025, $7.0 million for Q2 2025, and $172,000 during Q1 2025.